title: Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure.
abstract: Because of its intrinsic negative inotropic effect, the administration of the recently introduced calcium antagonist, verapamil, is thought to be contraindicated in presence of congestive heart failure (CHF). Yet, as CHF is frequently associated with arrhythmias and angina pectoris, and verapamil possesses potent antiarrhythmic and antianginal properties that could be of great benefit to selected patients with CHF, this study was undertaken to determine whether verapamil can be given to such subjects safely. For this purpose, 14 patients with CHF were studied in the control (preverapamil) state with a combined hemodynamic-cineangiographic approach; the same interventions were repeated during intravenous verapamil administration (0.1 mg/kg bolus, followed by 0.005 mg/kg/min infusion). Verapamil markedly lowered mean aortic pressure (95 +/- 19 to 81 +/- 12 mm Hg, p less than 0.001) and systemic vascular resistance (1,953 +/- 873 to 1,417 +/- 454 dynes s cm-5, p less than 0.01). Simultaneously, indexes of left ventricular (LV) performance substantially improved: the ejection fraction increased from 29 +/- 13 to 37 +/- 17% (p less than 0.01), and mean velocity of circumferential fiber shortening increased from 0.45 +/- 0.18 to 0.64 +/- 0.28 circ/s (p less than 0.001). Cardiac index also increased (from 1.98 +/- 0.49 liters/m2/min before verapamil to 2.24 +/- 0.60 liters/m2/min after verapamil), although this improvement did not become statistically significant. No appreciable changes were noted in the heart rate, LV end-diastolic pressure, or mean pulmonary arterial or pulmonary capillary wedge pressure. Thus, the intrinsic negative inotropic activity of intravenous verapamil in therapeutic doses generally does not represent a serious drawback even in patients with CHF; its potent unloading vasodilatory properties more than compensate for any intrinsic decrease in LV contractility, and can thereby actually improve overall cardiac function.
mesh_terms: D001011:Aorta / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D013318:Stroke Volume / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects; D014700:Verapamil / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
chemical_list: D014700:Verapamil